Does Anyone Have Any New Information About ATTP?(Acute Thrombosesis Thrombotnec Purpura)?

Question by CocoChanel: Does anyone have any new information about ATTP?(Acute Thrombosesis Thrombotnec Purpura)?
I spent 3 months in the hospital, underwent 2 surgeries, all of my organs failed, so I endured round after round of dialasis & blood transfusions. Not that I knew, I was in a coma on full life support for 2 &1/2 of those 3 months. I received “Last Rites” TWICE because the doctors assumed I would not survive long enough for my parish priest to arrive,so the hospital chaplain came by, just in case. My mother had to tell my son(who had recently turned10)that Mommy was going to Heaven soon. FINALLY, with the excellent notes of my rheumatologist, a visiting hemotologist worked through the choaos created by the other doctors. He diagnoised my ATTP. I received 11 rounds of ferrisis & woke up 17 hours after the final treatment.
Wow, you have no idea how difficult this was for me to write…
My point is this, it’s been 5 long hard years of recovery & RESEARCH,so aside from my need to just release all of this out into the void. Does anyone have any new information? (sorry for any S&G errors)

Best answer:

Answer by matador89
This is the latest report of research, I copy it here for you.

1: J Am Coll Cardiol. 2007 Sep 18;50(12):1138-43. Epub 2007 Sep 4. Links
Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.
Bennett CL, Kim B, Zakarija A, Bandarenko N, Pandey DK, Buffie CG, McKoy JM, Tevar AD, Cursio JF, Yarnold PR, Kwaan HC, De Masi D, Sarode R, Raife TJ, Kiss JE, Raisch DW, Davidson C, Sadler JE, Ortel TL, Zheng XL, Kato S, Matsumoto M, Uemura M, Fujimura Y; SERF-TTP Research Group.
VA Center for Management of Complex Chronic Care at Jesse Brown VA Medical Center, Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA. [email protected]
OBJECTIVES: We sought to describe clinical and laboratory findings for a large cohort of patients with thienopyridine-associated thrombotic thrombocytopenic purpura (TTP). BACKGROUND: The thienopyridine derivatives, ticlopidine and clopidogrel, are the 2 most common drugs associated with TTP in databases maintained by the U.S. Food and Drug Administration (FDA). METHODS: Clinical reports of TTP associated with clopidogrel and ticlopidine were identified from medical records, published case reports, and FDA case reports (n = 128). Duration of thienopyridine exposure, clinical and laboratory findings, and survival were recorded. ADAMTS13 activity (n = 39) and inhibitor (n = 30) were measured for a subset of individuals. RESULTS: Compared with clopidogrel-associated TTP cases (n = 35), ticlopidine-associated TTP cases (n = 93) were more likely to have received more than 2 weeks of drug (90% vs. 26%), to be severely thrombocytopenic (84% vs. 60%), and to have normal renal function (72% vs. 45%) (p < 0.01 for each). Compared with TTP patients with ADAMTS13 activity >15% (n = 13), TTP patients with severely deficient ADAMTS13 activity (n = 26) were more likely to have received ticlopidine (92.3% vs. 46.2%, p < 0.003). Among patients who developed TTP >2 weeks after thienopyridine, therapeutic plasma exchange (TPE) increased likelihood of survival (84% vs. 38%, p < 0.05). Among patients who developed TTP within 2 weeks of starting thienopyridines, survival was 77% with TPE and 78% without. CONCLUSIONS: Thrombotic thrombocytopenic purpura is a rare complication of thienopyridine treatment. This drug toxicity appears to occur by 2 different mechanistic pathways, characterized primarily by time of onset before versus after 2 weeks of thienopyridine administration. If TTP occurs after 2 weeks of ticlopidine or clopidogrel therapy, therapeutic plasma exchange must be promptly instituted to enhance likelihood of survival. PMID: 17868804 [PubMed - in process] You might find out more details if you contact the department where you were admitted. You might also be aware that enquiries were made in 1955 to determine the incidence and timing of relapses in patients who have recovered from an acute episode of thrombotic thrombocytopenic purpura. Hope this helps matador 89

Know better? Leave your own answer in the comments!

Mobile Number for a Inpatient Drug Rehab Around Chicago – For Drug Recovery Assistance Call 1-855-602-5102 24/7/365.